About Apceth
Apceth is a company based in Munchen (Germany) founded in 2007 was acquired by Hitachi Chemical in January 2019. Apceth operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Munchen, Germany
- SectorsHealthcare
- Website apceth.com
- Social LinkedIn
- Acquired by Hitachi Chemical (Jan 2019)
- InvestorsBMBF
& 1 more
- Acquired byHitachi Chemical
(Jan 2019)
Funding Insights of Apceth
- Total Rounds 2
- First Round $6.13M
(Jul 2010)
- Investors Count 1
All 2 funding rounds of Apceth with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2013 | – | Series A | β | β | β |
| Jul 2010 | $6.13M | Grant | β | β |
2 investors in total: 2 institutional.
Investors in Apceth
Apceth has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include BMBF and Hitachi Chemical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Education and research policies are overseen by the ministry. | 1955 | bmbf.de | Berlin, Germany | |
Manufacturer and supplier of electronic, resin, carbon & wiring board materials | 1962 | hitachi-chem.co.jp | San Jose, United States |
Investor details for Apceth
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Apceth
4 dated milestones of Apceth across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Apceth is founded.
- Funding First funding round of $6.1M.
- Funding Latest funding round, Series A,.
- Exit Acquired by Hitachi Chemical.
Competitors of Apceth
Apceth operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. |
Detailed competitors of Apceth
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Apceth
Websites that share an audience with Apceth (apceth.com).
Websites whose visitors overlap most with Apceth. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
transkript.de | transkript.de | 100% | – | #2,698,949 | β |
| paragonbioservices.com | 87% | – | – | View details | |
| brainstorm-cell.com | 86% | 4.5K | #4,620,847 | View details | |
| tigenix.com | 86% | – | – | View details | |
| reneuron.com | 55% | 1.4K | #13,333,853 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 7 similar websites and full traffic analytics for Apceth
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Apceth
Complete news archive for Apceth
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Apceth
10 companies that operate in the same segment as Apceth (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Apceth
Apceth was founded in 2007 and raised its 1st funding round 3 years after it was founded.
Apceth is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.
Apceth was founded in 2007 in Munich, Germany, focusing on biotechnology and cell therapy. Genetically modified mesenchymal stem cells (MSCs) form the basis of the platform technology. Therapeutics are developed targeting cancer, with Agenmestencel as the lead product in clinical trials. Additional candidates address lung diseases and inflammatory conditions through innovative cell-based approaches.
Apceth's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Apceth has 2 investors. Key investors include BMBF, and Hitachi Chemical.
Yes. Apceth was acquired by Hitachi Chemical in January 2019.